Targeting mTOR for cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates cellular growth and proliferation.
• Aberrant mTOR signaling is implicated in human cancers, making it a therapeutic target.
• Rapamycin and its analogs inhibit mTOR, demonstrating antitumor effects in preclinical models.

Purpose of the Study:

• To review the role of mTOR inhibitors in cancer therapy.
• To discuss challenges in the clinical development of mTOR inhibitors.
• To highlight the need for improved patient selection and understanding of response determinants.

Main Methods:

• Review of preclinical and clinical studies on mTOR inhibitors.
• Analysis of challenges in dose selection and pharmacodynamic assessment.
• Discussion of strategies for patient selection in clinical trials.

Main Results:

• mTOR inhibitors exhibit potent antitumor activity in vitro and in vivo.
• Clinical trials show antitumor effects in various refractory neoplasms.
• Challenges include dose selection based on toxicity and interpatient variability.

Conclusions:

• mTOR inhibitors are promising anticancer agents.
• Further research is required to optimize their clinical application.
• Understanding determinants of response is crucial for patient selection and effective treatment.